OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Molina on Information for the Public on Kidney Cancer

March 14th 2011

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York, shares information that she feels the public should know about kidney cancer.

Dr. Pearlstone on Biomarker Testing in the Community

March 14th 2011

David Pearlstone, MD, Co-Division Chief, Breast Oncology from John Theurer Cancer Center on Biomarker Testing in the Community Setting

Dr. Siegel on the Cost of Cancer Care

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on the escalating costs associated with cancer car

Dr. Alter on Kidney Injury in Relation to Patient Recovery

March 14th 2011

Dr. Robert Alter on ASCO GU-Kidney Cancer Findings

March 14th 2011

Dr. Molina on Her Recent Presentation at ASCO GU 2011

March 14th 2011

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York, talks about her presentation at 2011 ASCO Genitourinary conference.

Dr. Alter on 2011 ASCO GU Prostate Cancer Findings

March 14th 2011

Robert S. Alter, M.D. Co-chief, Urologic Oncology, John Theurer Cancer Center, on prostate cancer research that was presented at the 2011 ASCO Genitourinary meeting.

Dr. Alter Discusses Research at JTCC

March 14th 2011

Dr. Robert Alter on Current Research at John Theurer Cancer Center

Dr. Alter on Kidney Cancer Drugs From 2005-2010

March 14th 2011

Robert S. Alter, MD, Co-chief, Urologic Oncology, John Theurer Cancer Center, on kidney cancer drugs from the year 2005 to 2010.

Dr. Molina Talks About Her Involvement in Clinical Trials

March 14th 2011

Ana M. Molina, M.D. Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Talks About Her Involvement in New Clinical Trials

Dr. Molina Discusses Recent Pazopanib Clinical Trials

March 14th 2011

Ana M. Molina, MD, Genitourinary Oncology Service from Memorial Sloan-Kettering Cancer Center in New York Discusses Recent Pazopanib Clinical Trials.

Dr. Siegel Discusses Ongoing Myeloma Clinical Trials

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, discusses ongoing myeloma clinical trials in the spring of 2011.

Dr. Siegel Discusses Accelerated Drug Approval

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains his thoughts on accelerated drug approvals.

Dr. Siegel on Biomarkers and Molecular Analysis

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on biomarkers and molecular analysis.

Dr. Siegel on the PX-171-003-A1 Carfilzomib Study

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a clinical trial that looked at the newly approved agent carfilzomib.

Dr. Siegel on His Presentation at the 2010 ASH Meeting

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on his presentation at the 2010 American Society of Hematology (ASH) conference.

Dr. Siegel on the Practice Changes the Past 10 Years

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on how his practice has changed over the past 10 years.

Dr. Siegel on Drugs Discussed at the 2010 ASH Meeting

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on new drugs discussed at the 2010 American Society of Hematology Conference.

Dr. Siegel on the Carfilzomib FDA Approval Process

March 14th 2011

Dr. David Siegel from John Theurer Cancer Center on the Carfilzomib FDA Approval Process

Dr. Siegel on the Importance of Bisphosphonates

March 14th 2011

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates